Phase 3 Data Demonstrate TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine Significantly Improves Event-Free Survival and Overall Survival in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia
Dec 13, 2021
TIBSOVO in combination with azacitidine compared to placebo plus azacitidine also demonstrated significant improvements in complete remission rate, complete remission and complete remission with partial hematologic recovery rate and objective response rate Safety profile was favorable and consistent with previously published data Data from the Phase 3 AGILE trial of patients with previously untreated IDH1-mutated acute myeloid leukemia will be presented in an oral session on Monday, D